Stock analysis for Alnylam Pharmaceuticals Inc (ALNY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Alnylam Pharmaceuticals has annual revenue of $74.9M, total funding of $417.5M, has 1228 employees and grew their employee count by 31% last year. Find the latest Revenue & EPS data for Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) at Nasdaq.com. Alnylam (ALNY) delivered earnings and revenue surprises of 14.29% and 9.05%, respectively, for the quarter ended March 2020. Find detailed stats on Alnylam Pharmaceuticals revenue on Craft. Alnylam Pharmaceuticals Financials: This is the Financials-site for the company Alnylam Pharmaceuticals on Markets Insider ... Revenue: 438 840 1,464 2,169 Dividend: 0.00 0.00 - - Dividend … Alnylam Pharmaceuticals annual revenue increased from $74.9 million in 2018 to $219.8 million in 2019, a 193.4% increase. Do the numbers hold clues to what lies ahead for the stock? In depth view into Alnylam Pharmaceuticals Revenue (TTM) including historical data from 2004, charts, stats and industry comps.